[Intravitreal injections: Guidelines, methods and medicolegal issues].

Autor:	Ducloyer JB; Service d'ophtalmologie, CHU de Nantes, Nantes université, 1, place Alexis-Ricordeau, 44093 Nantes, France. Electronic address: Jeanbaptiste.ducloyer@chu-nantes.fr., Deltour JB; Service d'ophtalmologie, CHU de Nantes, Nantes université, 1, place Alexis-Ricordeau, 44093 Nantes, France., Le Meur G; Service d'ophtalmologie, CHU de Nantes, Nantes université, 1, place Alexis-Ricordeau, 44093 Nantes, France., Weber M; Service d'ophtalmologie, CHU de Nantes, Nantes université, 1, place Alexis-Ricordeau, 44093 Nantes, France.
Jazyk:	francouzština
Zdroj:	Journal francais d'ophtalmologie [J Fr Ophtalmol] 2023 Nov; Vol. 46 (9), pp. 1079-1086. Date of Electronic Publication: 2023 Oct 12.
DOI:	10.1016/j.jfo.2023.04.012
Abstrakt:	Intravitreal injection (IVI) of a drug allows for immediate intraocular concentrations of active ingredients higher than those obtained by intravenous injection while reducing the risk of systemic side effects. Today, IVI's play a central role in the treatment of many vitreoretinal diseases. With the aging of the population and the advent of vascular endothelial growth factor (VEGF) antagonists, their indications have increased exponentially, creating structural, organizational and economic difficulties. IVI is now one of the most widely performed medical procedures in industrialized countries, and its indications are expected to expand further in the near future with the development of new molecules. Although the overall safety of this practice is proven, an IVI exposes the patient to a 0.05 % risk of endophthalmitis, the consequences of which are often dramatic. This article details the current recommendations, in particular regarding asepsis and antisepsis, and proposes a typical sequence for performing an IVI. (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu